X4 Pharmaceuticals completes merger with Arsanis to advance rare disease and cancer treatments

X4 Pharmaceuticals has finalised its merger with Arsanis, creating a late-stage biopharmaceutical company focused on tackling rare diseases and cancer. This strategic move unites two ... Read More